Friday, May 6, 2011
Cadence Pharmaceuticals Inc., of San Diego, reported the company's first-ever revenue, with sales of recently launched Ofirmev (acetaminophen) injection, an intravenous formulation of acetaminophen, driving net revenue of $350,000.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.